Human‐host transcriptomic analysis reveals unique early innate immune responses in different sub‐phenotypes of COVID‐19

Abstract

The diverse clinical manifestations of COVID-19 are substantially modulated by host immune responses, emphasising the need for investigating the initial Transcriptional landscape leading to disease severity.1 This is the first study wherein host responses between sub-phenotypes—mild, moderate, severe and mortality—have been elucidated to identify disease regulatory genes. A total of 125 hospital-admitted patients were categorised into sub-phenotypes based on outcome (recovered, mortality) and disease severity (mild, moderate, severe). Following the Indian Council of Medical Research (ICMR) guidelines, shortness of breath (SOB), SpO2 and respiratory support (RS) requirements were used for severity classification. The clinical data highlighted that RS required by the patients did not always coincide with SpO2 levels and SOB, reinforcing analysis for differential host response with a single feature of RS requirement. The study design, including sample-wise segregation into multiple clinical subgroups, SpO2 and level of RS requirement, is depicted in Figure S1A,B. The significance analysis of clinical data for sub-phenotypes is provided in Tables S1 and S2. Pearson correlation analysis was performed to identify significant associations among clinical parameters (Figure S1C), specifically as demonstrated in Figure S1D–H. The methodology and literature supporting data interpretation are given as Supporting Information. Foremost, we wanted to identify a possible mechanism leading to recovery from COVID-19. Transcriptome analysis between recovered and mortality patients revealed 104 significant differentially expressed genes (DEGs), of which 93 were upregulated and 11 were downregulated (Supporting Information S1; Figure 1A). Several genes related to mucosal immunity (MUC1, MUC4, MUC20, MUC21),2 cell adhesion and cell–cell junction formation (TJP1, PARD3, ACTN4, ACTG1, EMP1, PPL), and cytoskeleton formation for epithelial cells (KRT4, KRT78, KRT19, KRT80, KRT16)3 were significantly upregulated in the recovered patients. The observed upregulated genes involved in the maintenance of epithelial integrity and mucosal immunity in recovered patients probably indicate an active defence against SARS-CoV-2 infection (Figure 1B). Pathway and network analysis (Figure 1C,D) concurred with the above results reflecting the maintenance of cell junction adherens and organisation of the protective airway epithelium. To understand differential disease severity within recovered, we looked further into the transcriptomic profile between mild, moderate, severe and mortality (Supporting Information S1; Figure 2A). Moderate and severe patients’ comparisons with mild revealed a distinct DEG profile, with 17 upregulated and two downregulated genes in moderate, whereas only six upregulated genes in severe compared to mild. Importantly, DEGs of the mortality patients highlighted the major downregulation of immune-related genes: 30/43, 3/7, 21/24 versus mild/moderate/severe, respectively (Figure 2B). The association of significant DEGs with age using logistic regression analysis revealed the non-dependence of the majority of genes (Supporting Information S2). The upregulation of IL1R2, HSPA1A, NLRP3, S100A2 and NOS2 in moderate patients plausibly indicates a closely regulated antiviral innate immune response that provides protection from SARS-CoV-2 infection and prevents the hyperinflammatory response.4-6 The DEGs of the mortality group (versus mild/moderate/severe) were functionally different and showed overall decreased expression. Of significant interest was the downregulation of MAL (MYD88 adaptor-like), an integral component of Toll-like receptor (TLR) signalling during pathogen invasion,7 and TRIM16, which regulates inflammasome activity through NLRP1-dependent production of IL-1B (Interleukin) and IL-18.8 ECM1, HSPB8, TGM3, TMPRSS11B, ITGA2, SLC20A2, ANXA11, S100A10 and IGFP3 were significantly downregulated in mortality patients, highlighting the possibility of a suboptimal innate immune response. The skewed upregulation of the chemokine CCL20 in mortality patients can be an inflammatory effector molecule generated due to SARS-CoV-2 infection and might be integral to COVID-19 severity.9 The heatmap highlights the differential abundance of genes across the clinical sub-phenotypes (Figure 2C). Enrichment of pathways associated with antiviral inflammatory immune signalling (Figure 2D) and protein–protein interaction analysis highlighting the cellular stress response (Figure 2E,F) highlights the state of active defence in moderate patients and a suboptimal immune response in mortality. Similarly, looking closely at the DEG profile between RS requirement subgroups: No-RS, RS and ventilator support (VS), we identified distinct DEGs for VS compared to RS and No-RS (Supporting Information S1; Figure 3A,B). Immune response genes with known roles in COVID-19 and other infectious diseases, IL22RA1, IFNE, CXCL14, CFD, CR2, IGHG3, IGLC2, C1QTNF4, C1QTNF7 and PCDHA7, were identified. The upregulation of several immune-related genes within the VS patients suggests a hyperactivated host response, leading to enhanced levels of cytokines and interleukins (Figure 3C). Findings were corroborated by pathway (chemokine signalling, JAK–STAT signalling, alternate and classical pathway of the complement system) and network analysis (Figure 3D,E). The DEGs for RS versus No-RS were similar to those of severity classification (Figure 3A–C). Subsequently, we elucidated the possibly altered immune mechanisms in the clinical sub-phenotypes. As illustrated in Figure 4A, upregulation of S100A2 and NLRP3 in moderate patients might provide a substantial immune-inflammatory response. A possible counteractive effect is observed by the upregulation of HSPA1A, where HSPA1A leads to inhibition of-Nuclear factor kappa B (NF-κB)-regulated NLR family pyrin domain containing 3 (NLRP3) inflammasome activation, thereby preventing exacerbation of inflammation.10 The mechanism for the deregulated host response due to downregulation of MAL and TRIM16 in mortality patients is also depicted in Figure 4A. MAL facilitates recruitment of MyD88, affecting TLR-2-, TLR-4- and RAGE-mediated downstream signalling leading to activation of the NF-κB pathway, the central regulator of innate immune signalling and inflammation. Figure 4B mechanistically illustrates the downstream signalling pathways affected by upregulated genes in VS patients. IFNE, a type I interferon, after sensing viral RNA is stimulated via Retinoic acid-inducible gene 1 (RIG-I) -like receptor signalling, establishing an antiviral response. IFNE and IL22RA1 lead to subsequent activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, which, through ISGF3 and TFEB, respectively, induces the expression of proinflammatory cytokines. Activation of the alternate complement pathway, directly by SARS-CoV-2 or via the JAK–STAT pathway, leads to endothelial and tissue injury. In summary, the expression of proinflammatory cytokines with tissue injury during the initial phase of SARS-CoV-2 infection can plausibly lead to a cytokine storm response in patients requiring VS. The study may benefit from longitudinal sampling of patients, different cohorts and variants of concern to understand the dynamic host response. Our study provides evidence for the presence of distinct immune mechanisms due to SARS-CoV-2 infection modulating different COVID-19 sub-phenotypes. The initial host transcriptome profile may help understand the future disease severity and outcome in COVID-19 patients. These findings can provide leads for prior targeted medical intervention and healthcare support. Initial Host Transcriptional landscape of COVID-19 sub-phenotypes holds key to disease severity and clinical outcome. Differential innate immune responses define moderate and mortality groups’ clinical phenotype. Possible immune mechanisms identified in patient sub-phenotypes can provide leads for targeted medical intervention and healthcare support. The authors declared that they have no conflict of interest exists. Bill and Melinda Gates Foundation (grant number: INV-033578). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Topics & Concepts